Search - tctmd.com

Displaying 421 - 440 of 1082

Sort: Relevancy | Date

My Takeaways From TCT 2017: Show Up, Keep It Civil, and Bring Your Best Self

News Opinion Editor's Corner TCT 2017

My Takeaways From TCT 2017: Show Up, Keep It Civil, and Bring Your Best Self

November 22, 2017

Long-Awaited Hypertension Guidelines Released at AHA

News Conference News AHA 2017

Long-Awaited Hypertension Guidelines Released at AHA

November 13, 2017

Experts Debate: Should Cerebral Protection Be Used for All TAVRs?

News Conference News TCT 2017

Experts Debate: Should Cerebral Protection Be Used for All TAVRs?

November 09, 2017

A-fib Signals Worse Prognosis After Aortic Valve Replacement in Intermediate-Risk Patients

News Conference News TCT 2017

A-fib Signals Worse Prognosis After Aortic Valve Replacement in Intermediate-Risk Patients

November 08, 2017

Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery

News Conference News TCT 2017

Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery

Yael L. Maxwell

October 31, 2017

Live From Denver: TCT 2017, Day Two

News Conference News TCT 2017

Live From Denver: TCT 2017, Day Two

October 31, 2017

News Opinion Off Script TCT 2017

Off Script: Welcome to TCT 2017 in the Mile High City

October 29, 2017

My Picks for Fellows Attending TCT 2017

News Opinion Fellow Talk

My Picks for Fellows Attending TCT 2017

Amit K. Gupta, MBBS, MD

October 26, 2017

TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More

News Conference News TCT 2017

TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More

October 20, 2017

What Works, What Matters? Patient-Centered Endpoints Gain Traction in CV Clinical Trials

News Daily News

What Works, What Matters? Patient-Centered Endpoints Gain Traction in CV Clinical Trials

October 13, 2017

Alirocumab Ban Reversed, New Trial Ordered in PCSK9 Patent Dispute

News Daily News

Alirocumab Ban Reversed, New Trial Ordered in PCSK9 Patent Dispute

Michael O'Riordan

October 10, 2017

Rivaroxaban Trial in Patients With Embolic Stroke of Undetermined Source Stopped Early

News Daily News

Rivaroxaban Trial in Patients With Embolic Stroke of Undetermined Source Stopped Early

October 09, 2017

News Industry News

Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death

October 02, 2017

Hemodynamics of First-Gen Sapien Valve Hold Up Well Over the Years: PARTNER Analysis

News Daily News

Hemodynamics of First-Gen Sapien Valve Hold Up Well Over the Years: PARTNER Analysis

September 29, 2017

Paravalvular Regurgitation With Sapien 3 Rare but Still Can Be Deadly

News Daily News

Paravalvular Regurgitation With Sapien 3 Rare but Still Can Be Deadly

Michael O'Riordan

September 27, 2017

Valve Deterioration and Durability Definitions Now Standardized in New Guide

News Conference News PCR London Valves 2017

Valve Deterioration and Durability Definitions Now Standardized in New Guide

September 25, 2017

TAVR Takeover? Experts Debate Timing of Surgery’s Ousting in Aortic Stenosis

News Conference News PCR London Valves 2017

TAVR Takeover? Experts Debate Timing of Surgery’s Ousting in Aortic Stenosis

September 24, 2017

News Industry News

Medtronic IN.PACT Admiral DCB Global Two Year Data and IN.PACT SFA Four Year Data Presented in VIVA Late Breaking Clinical Trials

September 12, 2017

News Industry News

The Cardiovascular Research Foundation Appoints Dr. Juan F. Granada as President and Chief Executive Officer

September 11, 2017

European Societies Issue New Valvular Heart Disease Guidelines, With Important Shifts

News Conference News ESC 2017

European Societies Issue New Valvular Heart Disease Guidelines, With Important Shifts

August 27, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.